Skip to main content

Table 1 Linear Mixed Model Effect Estimates of Treatment Group on Ocular Parameters

From: Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety

Time point\Group

Placebo

0.1% loading dosea

0.01%b

AL, mm

Baseline

24.60 (24.35; 24.86)

9-mo

24.88 (24.56; 25.20)

−0.11 (− 0.17; −0.04)

−0.07 (− 0.13; 0.00)

12-mo

24.94 (24.62; 25.26)

−0.10 (− 0.17; −0.02)

−0.07 (− 0.15; 0.00)

12-mo adjusted-p

 

0.06

0.16

SER, diopters

Baseline

−2.99 (− 3.37; −2.60)

9-mo

−3.57 (− 4.11; −3.03)

0.35 (0.17; 0.52)

0.18 (0.00; 0.35)

12-mo

−3.64 (− 4.19; −3.09)

0.24 (0.05; 0.42)

0.19 (0.00; 0.38)

12-mo adjusted-p

 

0.06

0.14

IOP, mmHg

Baseline

16.1 (15.3; 17.0)

9-mo

16.7 (14.6; 18.9)

-0.3 (-1.8; 1.2)

-0.7 (-2.2; 0.8)

12-mo

16.6 (14.5; 18.8)

0.2 (-1.3; 1.7)

0.0 (-1.5; 1.5)

12-mo adjusted-p

 

0.88

0.98

Distance BCVA, LogMAR

Baseline

−0.10 (− 0.12; −0.09)

9-mo

−0.11 (− 0.15; −0.07)

−0.01 (− 0.03; 0.01)

0.01 (− 0.01; 0.04)

12-mo

−0.12 (− 0.16; −0.08)

−0.02 (− 0.04; 0.01)

−0.00 (− 0.03; 0.02)

12-mo adjusted-p

 

0.42

0.88

Near BCVA, LogMAR

Baseline

−0.07 (− 0.09; −0.05)

9-mo

−0.06 (− 0.12; −0.01)

−0.02 (− 0.06; 0.02)

0.00 (− 0.04; 0.04)

12-mo

−0.09 (− 0.14; −0.04)

−0.01 (− 0.04; 0.02)

0.01 (− 0.02; 0.04)

12-mo adjusted-p

 

0.78

0.52

Accommodation amplitude, diopters

Baseline

16.4 (15.3; 17.5)

9-mo

15.4 (12.9; 17.0)

−0.8 (− 2.2; 0.6)

−0.2 (− 1.6; 1.2)

12-mo

16.1 (14.2; 19.1)

−0.7 (− 2.2; 0.8)

−1.0 (− 2.5; 0.5)

12-mo adjusted-p

 

0.52

0.32

Mesopic pupil diameter, mm

Baseline

4.14 (3.92; 4.36)

9-mo

4.07 (3.59; 4.55)

0.31 (0.01; 0.62)

0.54 (0.24; 0.85)

12-mo

4.10 (3.62; 4.57)

0.43 (0.13; 0.72)

0.51 (0.21; 0.80)

12-mo adjusted-p

 

0.02*

0.006*

Photopic pupil diameter, mm

Baseline

2.71 (2.61; 2.81)

9-mo

2.67 (2.46; 2.89)

0.21 (0.08; 0.35)

0.23 (0.10; 0.36)

12-mo

2.67 (2.45; 2.89)

0.18 (0.04; 0.33)

0.22 (0.08; 0.36)

12-mo adjusted-p

 

0.05*

0.01*

  1. Effect estimates for the placebo group are total to the given time point while effect estimates for the intervention groups (0.1% loading dose and 0.01%) are differences from the placebo group at the given time point. The baseline effect estimates are means across all groups at baseline. Abbreviations: AL, axial length; BCVA, best-corrected visual acuity; mo, months; p, p-value; adjusted-p, p-value adjusted by False Discovery Rate; SER, Spherical equivalent refraction
  2. a Change in the 0.1% loading dose group compared to placebo at the given time point
  3. b Change in the 0.01% group compared to placebo at the given time point
  4. * Statistically significant below our adjusted-p cut-off of 0.05
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us